Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naïve chronic hepatitis B patients in the real-world setting

Summary The aim of this study was to determine the long‐term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the natural course of disease in chronic hepatitis B patients (CHB) with/without cirrhosis in clinical practice. A total of 355 treatment‐naïve CHB patients were enroll...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of viral hepatitis 2015-05, Vol.22 (5), p.504-510
Hauptverfasser:	Idilman, R., Gunsar, F., Koruk, M., Keskin, O., Meral, C. E., Gulsen, M., Elhan, A. H., Akarca, U. S., Yurdaydin, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - epidemiology chronic hepatitis B Creatinine - blood DNA, Viral - blood entecavir Female Guanine - analogs & derivatives Guanine - therapeutic use Hepatitis B e Antigens - blood Hepatitis B virus - isolation & purification Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy hepatocellular carcinoma Humans Incidence Liver Neoplasms - epidemiology Male Metabolic Clearance Rate Middle Aged Prospective Studies Retrospective Studies Tenofovir - therapeutic use tenofovir disoproxil fumarate Treatment Outcome Viral Load
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary The aim of this study was to determine the long‐term efficacy of entecavir (ETV) and tenofovir disoproxil fumarate (TDF) on the natural course of disease in chronic hepatitis B patients (CHB) with/without cirrhosis in clinical practice. A total of 355 treatment‐naïve CHB patients were enrolled into the study. The primary outcome measure was viral suppression as defined by serum HBV DNA level
ISSN:	1352-0504 1365-2893
DOI:	10.1111/jvh.12358